2026 MaTOS GU | Session IX | Bladder Cancer
Overview
Dr. Al-Ahmadi: bladder cancer subtypes vary in biology and outcomes; accurate classification and molecular profiling are key to guiding treatment.
Dr. Jain: Neoadjuvant ADCs in MIBC show high pCR rates; EVP outperforms chemo but has toxicity; future trials aim to refine use and avoid overtreatment.
Dr. Johnson: ctDNA in urothelial cancer guides periop care: clearance predicts outcomes; trials show ICI benefit, with ctDNA status aiding risk stratification and treatment.
Dr. Brown: Post EV+pembro UC: many need 2L therapy; platinum, HER2, FGFR inhibitors show activity; novel ADCs and vaccines show early promise.
Dr. Vaena: ADCs targeting B7H3, HER2, TROP2 show promise but have toxicity risks; ctDNA and genomics may guide safer, personalized treatment strategies.
Dr. Siefker-Radtke: Variant histology in UC affects outcomes; chemo helps small cell types, IO shows promise; need better trials and HER2-targeted ADC strategies.
Panel: Even minor variant histology matters; ctDNA may guide MRD but needs data; EV+pembro favored for lower toxicity; de-escalation trials needed.
Dr. Jain: Neoadjuvant ADCs in MIBC show high pCR rates; EVP outperforms chemo but has toxicity; future trials aim to refine use and avoid overtreatment.
Dr. Johnson: ctDNA in urothelial cancer guides periop care: clearance predicts outcomes; trials show ICI benefit, with ctDNA status aiding risk stratification and treatment.
Dr. Brown: Post EV+pembro UC: many need 2L therapy; platinum, HER2, FGFR inhibitors show activity; novel ADCs and vaccines show early promise.
Dr. Vaena: ADCs targeting B7H3, HER2, TROP2 show promise but have toxicity risks; ctDNA and genomics may guide safer, personalized treatment strategies.
Dr. Siefker-Radtke: Variant histology in UC affects outcomes; chemo helps small cell types, IO shows promise; need better trials and HER2-targeted ADC strategies.
Panel: Even minor variant histology matters; ctDNA may guide MRD but needs data; EV+pembro favored for lower toxicity; de-escalation trials needed.
Target Audience
Physicians
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Speakers and Panelists:
Hikmat Al-Ahmadie, MD
Rohit K. Jain, MD, MPH
Burles A. Johnson, III, MD, PhD
Jason R. Brown, MD, PhD
Daniel Vaena, MD
Arlene O. Sieher-Radtke, MD
Date of Release
March 20th, 2026
%2016.47.03-1770752981975.webp&w=3840&q=75)
